Fecal Microbiota Transplantation in Liver Diseases and Recent Developments
Authors
Abstract:
Introduction: The intestine, as an important part of the human gastrointestinal tract, provides a favorable milieu for the growth and development of a diverse and large population (approximately 1000 species) of bacteria. Currently, the presence of a cohesive relationship between intestinal bacteria and the host is being well studied and identified. According to the available scientific evidence, the establishment of conditions of imbalance (dysbiosis) in the number and diversity of intestinal microbiome causes the onset/progression of acute and chronic liver disorders (fatty liver, cirrhosis, and liver autoimmune disease). Therefore, modifying the balance and creating conditions of microbial eubiosis by fecal microbiota transplantation can be considered as a novel and host-compatible biological approach in the supportive treatment of liver diseases. Consequently, in the present study, while referring to investigations related to the focus of intestinal microbiome and their relation to liver diseases, the existing scientific evidence on the clinical efficacy of fecal microbiota transplantation in the treatment of some liver diseases and recent advances are discussed. Conclusion: Both basic science research and clinical studies have proven that the fecal microbiota transplantation method can effectively strengthen and improve the gut microbiota during acute and chronic liver diseases, rebuild and restore the balance of the gut microbiome, and accelerate the patient's recovery.
similar resources
Fecal Microbiota Transplantation and the Brain Microbiota in Neurological Diseases
The review by Choi and Cho, published in the May 2016 issue of Clinical Endoscopy, describes the therapeutic role of fecal microbiota transplantation (FMT) in non-gastrointestinal (GI) disorders that include neurological and psychiatric conditions such as autism, chronic fatigue syndrome, mood disorders, multiple sclerosis, and Parkinson’s disease. The Authors report clinical evidence that desc...
full textFecal Microbiota Transplantation.
In another feature article, Dr Paul Fitzmorris and Dr Ashwani K. Singal discuss surveillance and diagnosis of hepatocellular carcinoma, the third leading cause of cancer-related death worldwide. Physicians continue to underutilize surveillance techniques, which can identify hepatocellular carcinoma at an early stage and thereby improve prognosis. A practical approach to therapeutic drug monitor...
full textFecal Microbiota Transplantation
Thomas J. Borody has a pecuniary interest in the Centre for Digestive Diseases, where fecal microbiota transplantation is a treatment option for patients and has filed patents in this area; Jordana Campbell has no financial interest or affiliation with any institution, organization, or company relating to the article. No support or funding, including pharmaceutical and industry support, was rec...
full textExploring the Efficacy of Pooled Stools in Fecal Microbiota Transplantation for Microbiota-Associated Chronic Diseases
Fecal microbiota transplantation is being assessed as a treatment for chronic microbiota-related diseases such as ulcerative colitis. Results from an initial randomized trial suggest that remission rates depend on unobservable features of the fecal donors and observable features of the patients. We use mathematical modeling to assess the efficacy of pooling stools from different donors during m...
full textRecent advances in clinical practice DEVELOPMENTS IN LIVER TRANSPLANTATION
Correspondence to: Professor J M Neuberger, The Liver Unit, Queen Elizabeth Hospital, Birmingham B15 2TH, UK; James.Neuberger@ uhb.nhs.uk _________________________ I n the last few years, there have developments in many aspects of liver transplantation. This review will focus on those areas where adult clinical practice has developed; the topics selected are those which, it is hoped, will be of...
full textFecal Microbiota Transplantation: Patient and Physician Attitudes
Fecal microbiota transplantation (FMT) has been shown in numerous case series to be a rapidly acting (within hours to weeks), safe (no serious adverse effects definitely attributed to FMT), and highly effective (worldwide average success rate, 91%) therapy for recurrent Clostridium difficile infection (CDI), even when all other treatments have failed. At present, there remain only 2 impediments...
full textMy Resources
Journal title
volume 30 issue 9
pages 5183- 5203
publication date 2022-12
By following a journal you will be notified via email when a new issue of this journal is published.
No Keywords
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023